Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-12-29
2010-12-07
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C436S063000
Reexamination Certificate
active
07846899
ABSTRACT:
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
REFERENCES:
patent: 4691009 (1987-09-01), Palmer et al.
patent: 4820514 (1989-04-01), Cummins
patent: 4917826 (1990-04-01), Johnson et al.
patent: 5266562 (1993-11-01), Mukherjee et al.
patent: 5354269 (1994-10-01), Goodheart et al.
patent: 5470885 (1995-11-01), Fuhrman et al.
patent: 5482930 (1996-01-01), Wei et al.
patent: 5491130 (1996-02-01), Roberts et al.
patent: 5618786 (1997-04-01), Roosdorp et al.
patent: 5696092 (1997-12-01), Patierno et al.
patent: 5817750 (1998-10-01), Ruoslahti et al.
patent: 6066724 (2000-05-01), Ni et al.
patent: 6255281 (2001-07-01), Pilon et al.
patent: 2002/0006640 (2002-01-01), Ni et al.
patent: 2002/0025510 (2002-02-01), Strongin et al.
patent: 2002/0160948 (2002-10-01), Pilon et al.
patent: 2002/0169108 (2002-11-01), Pilon et al.
patent: 2002/0173460 (2002-11-01), Pilon et al.
patent: 2003/0008816 (2003-01-01), Pilon et al.
patent: 2003/0109429 (2003-06-01), Pilon et al.
patent: 2004/0047857 (2004-03-01), Pilon et al.
patent: 2005/0261180 (2005-11-01), Pilon et al.
patent: 2006/0025348 (2006-02-01), Pilon et al.
patent: 2006/0281681 (2006-12-01), Pilon et al.
patent: 2008/0064633 (2008-03-01), Pilon et al.
patent: 0617965 (1994-03-01), None
patent: 0617965 (1994-10-01), None
patent: WO 88/08983 (1988-11-01), None
patent: 9608572 (1996-03-01), None
patent: WO 96/09831 (1996-04-01), None
patent: 9640657 (1996-12-01), None
patent: WO 98/40657 (1996-12-01), None
patent: 9701627 (1997-01-01), None
patent: 9952493 (1999-10-01), None
Vasanthakumar et al., Chem Pharmacol. 1988;37(3):389-394).
Miller TL, Shashikant BN, Pilon AL, Pierce RA, Shaffer TH, Wolfson MR. Effects of an intratracheally delivered anti-inflammatory protein (rhCC10) on physiological and lung structural indices in a juvenile model of acute lung injury. Biol Neonate. 2006;89(3):159-70. Epub Oct. 6, 2005.
Shashikant BN, Miller TL, Welch RW, Pilon AL, Shaffer TH, Wolfson MR. Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. J Appl Physiol. Dec. 2005;99(6):2204-11. Epub Aug. 4, 2005.
Mandal AK, Ray R, Zhang Z, Chowdhury B, Pattabiraman N, Mukherjee AB. Uteroglobin inhibits prostaglandin F2alpha receptor-mediated expression of genes critical for the production of pro-inflammatory lipid mediators. J Biol Chem. Sep. 23, 2005;280(38):32897-904. Epub Aug. 1, 2005.
Mattsson J, Remberger M, Andersson O, Sundberg B, Nord M. Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. Transplantation. May 27, 2005;79(10):1411-6.
Welty SE. CC10 administration to premature infants: in search of the “silver bullet” to prevent lung inflammation. Pediatr Res. Jul. 2005;58(1):7-9. Epub May 5, 2005.
Benson M, Jansson L, Adner M, Luts A, Uddman R, Cardell LO. Gene profiling reveals decreased expression of uteroglobin and other anti-inflammatory genes in nasal fluid cells from patients with intermittent allergic rhinitis. Clin Exp Allergy. Apr. 2005;35(4):473-8.
Johansson S, Keen C, Ståhl A, Wennergren G, Benson M. Low levels of CC16 in nasal fluid of children with birch pollen-induced rhinitis. Allergy. May 2005;60(5):638-42.
Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res. Jul. 2005;58(1):15-21. Epub Mar. 17, 2005.
Ray R, Choi M, Zhang Z, Silverman GA, Askew D, Mukherjee AB. Uteroglobin suppresses SCCA gene expression associated with allergic asthma. J Biol Chem. Mar. 18, 2005;280(11):9761-4. Epub Jan. 27, 2005.
Yoshikawa S, Miyahara T, Reynolds SD, Stripp BR, Anghelescu M, Eyal FG, Parker JC. Clara cell secretory protein and phospholipase A2 activity modulate acute ventilator-induced lung injury in mice. J Appl Physiol. Apr. 2005;98(4):1264-71. Epub Dec. 17, 2004.
Ye Q, Fujita M, Ouchi H, Inoshima I, Maeyama T, Kuwano K, Horiuchi Y, Hara N, Nakanishi Y. Serum CC-10 in inflammatory lung diseases. Respiration. Sep.-Oct. 2004;71(5):505-10.
Hung CH, Chen LC, Zhang Z, Chowdhury B, Lee WL, Plunkett B, Chen CH, Myers AC, Huang SK. Regulation of TH2 responses by the pulmonary Clara cell secretory 10-kd protein. J Allergy Clin Immunol. Sep. 2004;114(3):664-70.
Mandal AK, Zhang Z, Ray R, Choi MS, Chowdhury B, Pattabiraman N, Mukherjee AB. Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions. J Exp Med. May 17, 2004;199(10):1317-30.
Iannuzzi MC. Clara cell protein in sarcoidosis: another job for the respiratory tract protector? Am J Respir Crit Care Med. Jan. 15, 2004;169(2):143-4.
Nosratabadi AR, Ljungman AG, Lindahl M, Welch R, Pilon A, Tagesson C. Clara cell 10-KDA protein inhibits endotoxin-induced airway contraction in isolated perfused rat lungs. Exp Lung Res. Oct.-Nov. 2003;29(7):455-73.
Ramsay PL, Luo Z, Major A, Park MS, Finegold M, Welty SE, Kwak I, Darlington G, Demayo FJ. Multiple mechanisms for oxygen-induced regulation of the Clara cell secretory protein gene. FASEB J. Nov. 2003;17(14):2142-4. Epub Sep. 18, 2003.
Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol. Jul. 15, 2003;171(2):1051-60.
Chandra S, Davis JM, Drexler S, Kowalewska J, Chester D, Koo HC, Pollack S, Welch R, Pilon A, Levine CR. Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury. Pediatr Res. Oct. 2003;54(4):509-15. Epub Jun. 18, 2003.
Shijubo N, Kawabata I, Sato N, Itoh Y. Clinical aspects of Clara cell 10-kDa protein/ uteroglobin (secretoglobin 1A1). Curr Pharm Des. 2003;9(14):1139-49. Review.
Van Bisbergen et al, “Synthetic peptide from lipocortin 1 has no phospholipase inhibitory activity,” FEBS Lett., vol. 247, pp. 293-297 (1989).
Van Vyve et al., “Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects”, J. of Allergy and Clin. Immun., vol. 95 No. 1 pp. 60-68 (1995).
Van Winkle, L. et al., “Repair of Naphthalene-Injured Microdissected Airways In vitro” American Journal of Respiratory Cell and Molecular Biology, vol. 15: 1-8 (1996).
Vasanthakumar, G., “Inhibition of Phagocyte Chemotaxis by Uteroglobin, An Inhibitor of Blastocyst Rejection”, Biochemical Pharmacology, vol. 37, No. 3: 389-394 (1988).
Volovitz, B. et al., “Relationship Between Leukotriene C4 and a Uteroglobin-Like Protein in Nasal and Tracheobronchial Mucosa of Children” Int. Arch. Allergy Applied Immunology, vol. 86: 420-425 (1988).
Vostal, J. et al., “Novel Peptides Derived From a Region of Local Homology Between Uteroglobin and Lipocortin-1 Inhibit Platelet Aggregation and Secretion”, Biochemical and Biophysical Research Communications, vol. 165, No. 1: 27-36 (1989).
Wu, C., et al. “Integrin Activation and Cytoskeletal Interaction Are Essential for the Assembly of a Fibronectin Matrix”, Cell, vol. 83: 715-724 (1995).
Wuenschell et al, “Embryonic mouse lung epithelial progenitor cells . . . ,” J. Histochem Cytochem, vol. 44, pp. 113-123 (1996).
Wuenschel
Cittone Henry J.
Cittone & Lindenbaum LLP
Clarassance, Inc.
Woodward Cherie M
LandOfFree
Methods and compositions for the reduction of neutrophil... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the reduction of neutrophil..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the reduction of neutrophil... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219780